PT-141 (Bremelanotide): Uses, FDA Approval, How It Works & Safety
PT-141 is the name commonly used in peptide and wellness communities for bremelanotide, a melanocortin receptor agonist. Unlike PDE5 inhibitors, bremelanotide acts through central melanocortin pathways rather than primarily through peripheral nitric-oxide signaling.
The short answer: FDA-approved bremelanotide (Vyleesi) is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) meeting specific criteria. It is not FDA approved to enhance sexual performance, and the approved labeling states that it is not indicated for men or postmenopausal women. Read the FDA prescribing information.
How does bremelanotide work?
Bremelanotide is a melanocortin receptor agonist. Its therapeutic effect is thought to involve central nervous system pathways associated with sexual desire.
That mechanism makes it different from drugs whose primary effect is increasing penile blood flow.
What is HSDD?
HSDD involves persistently low sexual desire that causes meaningful distress or interpersonal difficulty and is not better explained by another medical or psychiatric condition, relationship problems, or medication/substance effects.
That definition matters. Low desire can have many causes, including hormonal changes, medications, pain, depression, relationship stress and sleep problems.
Who is the FDA-approved medication for?
According to FDA labeling, Vyleesi is indicated for premenopausal women with acquired, generalized HSDD.
The label specifically states:
- it is not indicated for HSDD in postmenopausal women
- it is not indicated in men
- it is not indicated to enhance sexual performance
This is more precise than the common online claim that “PT-141 works for libido in both men and women.”
What are important safety considerations?
Bremelanotide can transiently increase blood pressure and reduce heart rate. Nausea is also a commonly discussed adverse effect.
The FDA label contains contraindications and instructions around dosing frequency and cardiovascular risk. A clinician should review those factors before prescribing an approved bremelanotide product.
Axiom Healthspan’s clinician-reviewed health optimization programs can provide a structured intake pathway for patients exploring sexual wellness and related goals.
Frequently asked questions
Is PT-141 the same as bremelanotide?
PT-141 is the development name commonly used for bremelanotide. Product formulation and regulatory status still matter.
Is bremelanotide Viagra for women?
No. The mechanism, indication and clinical use are different from PDE5 inhibitors such as sildenafil.
Is PT-141 FDA approved for men?
The FDA-approved bremelanotide product is not indicated for men.
Does bremelanotide automatically increase sexual performance?
No. FDA labeling explicitly states that it is not indicated to enhance sexual performance.
Bottom line
Bremelanotide is a real prescription therapy with an FDA-approved indication—but that indication is narrower than many online descriptions suggest. Sexual-health treatment works best when the cause of symptoms and the patient’s medical history are evaluated rather than treating libido as a one-variable problem.
Sources
- FDA — Vyleesi (Bremelanotide) Prescribing Information
- Axiom Healthspan — Clinician-Reviewed Programs
Educational information only. Sexual-health symptoms and prescription treatment require individualized clinical evaluation.
